Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data presented from early breast cancer treatment trial
January 6th, 2005
New data presented from the world's largest early breast cancer treatment trial (ATAC) report that ARIMIDEX reduced the relative risk of breast cancer recurrence by 17% over tamoxifen in the clinically relevant hormone receptor-positive patients for whom ARIMIDEX is indicated. The presentation also reviewed the safety profile of ARIMIDEX compared to tamoxifen after 68 months of follow-up. ARIMIDEX and tamoxifen remain the only drugs approved by the FDA for the primary (treatment following surgery, with or without radiation) adjuvant treatment of hormone receptor-positive postmenopausal women with early breast cancer. "It is crucial for women to...
Source: Women's Health Weekly (2005-01-06)
|
